Thiazolides, a novel class of anti-infective drugs, effective against viruses, bacteria, intracellular and extracellular protozoan parasites and proliferating mammalian cells

Anti-Infective Agents

Volumn 11, Issue 1, 2012, Pages 22-30

  Hemphill, Andrew ^a   Müller, Norbert ^a   Müller, Joachim ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antihelminthic; Antiprotozoal; Antiviral; Drug target identification; Salicylic acid; Thiazole

Indexed keywords

NITAZOXANIDE; RM 4819; RM 4847; THIAZOLE DERIVATIVE; TIZOXANIDE; UNCLASSIFIED DRUG;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; BACTERIUM; CELL PROLIFERATION; CESTODE; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; INNATE IMMUNITY; NEMATODE; NONHUMAN; PARASITE; PROTOZOON;

EID: 84872224857     PISSN: 22113525     EISSN: 22113533     Source Type: Journal    
DOI: 10.2174/22113626130103     Document Type: Article

References (74)

1. NDA filed for nitazoxanide. AIDS Patient Care STDS, 1998, 12 (5), 409-410.
2. Nitazoxanide (Alinia)--a new anti-protozoal agent. Med. Lett. Drugs Ther., 2003, 45 (1154), 29-31.
3. Arya, S. C. Nitazoxanide as a broad-spectrum antiparasitic agent. J. Infect. Dis., 2002, 185 (11), 1692.
4. White, A. C. Nitazoxanide: an important advance in anti-parasitic therapy. Am. J. Trop. Med. Hyg., 2003, 68 (4), 382-383.
5. Hemphill, A.; Mueller, J.; Esposito, M. Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. Expert. Opin. Pharmacother., 2006, 7 (7), 953-964.
6. Anderson, V. R.; Curran, M. P. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs, 2007, 67 (13), 1947-1967.
7. Hemphill, A., Müller, N., Müller, J. Structure-function relationship of thiazolides, a novel class of anti-parasitic drugs, investigated in intracellular and extracellular protozoan parasites and larval-stage cestodes. Antiinfective Agents Med. Chem., 2007, 6, 273-282.
8. Zhao, Z.; Xue, F.; Zhang, L.; Zhang, K.; Fei, C.; Zheng, W.; Wang, X.; Wang, M.; Meng, X. The pharmacokinetics of nitazoxanide active metabolite (tizoxanide) in goats and its protein binding ability in vitro. J. Vet. Pharmacol. Ther., 2010, 33 (2), 147-153.
9. Broekhuysen, J.; Stockis, A.; Lins, R. L.; De Graeve, J.; Rossignol, J. F. Nitazoxanide: pharmacokinetics and metabolism in man. Int. J. Clin. Pharmacol. Ther., 2000, 38 (8), 387-394.
10. Esposito, M.; Müller, N.; Hemphill, A. Structure-activity relationships from in vitro efficacies of the thiazolide series against the intracellular apicomplexan protozoan Neospora caninum. Int. J. Parasitol., 2007, 37 (2), 183-190.
11. Ballard, T. E.; Wang, X.; Olekhnovich, I.; Koerner, T.; Seymour, C.; Salamoun, J.; Warthan, M.; Hoffman, P. S.; Macdonald, T. L. Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity. Chem. Med. Chem., 2011, 6 (2), 362-377.
12. Murphy, J. R.; Friedmann, J. C. Pre-clinical toxicology of nitazoxanide-a new antiparasitic compound. J. Appl. Toxicol., 1985, 5 (2), 49-52.
13. Stockis, A.; De Bruyn, S.; Gengler, C.; Rosillon, D. Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d. Int. J. Clin. Pharmacol. Ther., 2002, 40 (5), 221-227.
14. Galvan-Ramirez, M. L.; Rivera, N.; Loeza, M. E.; Avila, X.; Acero, J.; Troyo, R.; Bernal, R. Nitazoxanide in the treatment of Ascaris lumbricoides in a rural zone of Colima, Mexico. J. Helminthol., 2007, 81 (3), 255-259.
15. Chero, J. C.; Saito, M.; Bustos, J. A.; Blanco, E. M.; Gonzalvez, G.; Garcia, H. H.; Peru, C. W. G. Hymenolepis nana infection: symptoms and response to nitazoxanide in field conditions. Trans. R. Soc. Trop. Med. Hyg., 2007, 101 (2), 203-205.
16. Lateef, M.; Zargar, S. A.; Khan, A. R.; Nazir, M.; Shoukat, A. Successful treatment of niclosamide-and praziquantel-resistant beef tapeworm infection with nitazoxanide. Int. J. Infect. Dis., 2008, 12 (1), 80-82.
17. Palomares-Alonso, F.; Piliado, J. C.; Palencia, G.; Ortiz-Plata, A.; Jung-Cook, H., Efficacy of nitazoxanide, tizoxanide and tizoxanide/albendazole sulphoxide combination against Taenia crassiceps cysts. J. Antimicrob. Chemother., 2007, 59 (2), 212-218.
18. Rao, R. U.; Huang, Y.; Fischer, K.; Fischer, P. U.; Weil, G. J. Brugia malayi: Effects of nitazoxanide and tizoxanide on adult worms and microfilariae of filarial nematodes. Exp. Parasitol., 2009, 121 (1), 38-45.
19. Delgado, O. M.; Fernandez, G.; Silva, S.; Ramirez, O.; Romero, J.; Rodriguez-Morales, A.J. Preliminary evidence of nitazoxanide activity on Toxocara canis in a mouse model. Int. J. Antimicrob. Agents, 2008, 31 (2), 182-184.
20. Gavidia, C. M.; Gonzalez, A. E.; Lopera, L.; Jayashi, C.; Angelats, R.; Barron, E. A.; Ninaquispe, B.; Villarreal, L.; Garcia, H. H.; Verastegui, M. R.; Gilman, R. H. Evaluation of nitazoxanide and oxfendazole efficacy against cystic echinococcosis in naturally infected sheep. Am. J. Trop. Med. Hyg., 2009, 80 (3), 367-372.
21. Pérez-Molina, J. A.; Díaz-Menéndez, M.; Gallego, J. I.; Norman, F.; Monge-Maillo, B.; Ayala, A. P.; López-Vélez, R. Evaluation of nitazoxanide for the treatment of disseminated cystic echinococcosis: report of five cases and literature review. Am. J. Trop. Med. Hyg., 2011, 84 (2), 351-356.
22. Schipper, H. G.; Simsek, S.; van Agtmael, M. A.; van Lienden, K. P. Bone hydatid disease refractory to nitazoxanide treatment. Am. J. Trop. Med. Hyg., 2009, 81 (3), 446-448.
23. Tappe, D.; Müller, A.; Frosch, M.; Stich, A. Limitations of amphotericin B and nitazoxanide in the treatment of alveolar echinococcosis. An. n Trop. Med. Parasitol. 2009, 103 (2), 177-181.
24. Stadelmann, B.; Müller, J.; Hemphill, A. Application of an in vitro drug screening assay based on the release of phosphoglucose isomerase to determine the structure-activity relationship of thiazolides against Echinococcus multilocularis metacestodes. J. Antimicrob. Chemother. 2010, 65, 512-519.
25. Escobedo, A. A.; Alvarez, G.; González, M. E.; Almirall, P.; Cañete, R.; Cimerman, S.; Ruiz, A.; Pérez, R. The treatment of giardiasis in children: single-dose tinidazole compared with 3 days of nitazoxanide. Ann. Trop. Med. Parasitol., 2008, 102 (3), 199-207.
26. Rossignol, J. F.; Kabil, S. M.; El-Gohary, Y.; Younis, A. M. Nitazoxanide in the treatment of amoebiasis. Trans. R. Soc. Trop. Med. Hyg., 2007, 101 (10), 1025-1031.
27. Dan, M.; Sobel, J. D. Failure of nitazoxanide to cure trichomoniasis in three women. Sex. Transm. Dis., 2007, 34 (10), 813-814.
28. Freeman, J.; Baines, S. D.; Todhunter, S. L.; Huscroft, G. S.; Wilcox, M. H. Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole. J. Antimicrob. Chemother., 2011, 66 (6), 1407-1408.
29. Musher, D. M.; Logan, N.; Mehendiratta, V.; Melgarejo, N. A.; Garud, S.; Hamill, R. J. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J. Antimicrob. Chemother., 2007, 59 (4), 705-710.
30. Yangco, B. G.; Sher, G.; Bardin, M. C. Nitazoxanide and probiotics for the treatment of recurrent Clostridium difficile infection in a peritoneal dialysis patient. South. Med. J., 2009, 102 (7), 746-747.
31. Musher, D. M.; Logan, N.; Bressler, A. M.; Johnson, D. P.; Rossignol, J. F. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin. Infect. Dis., 2009, 48 (4), e41-6.
32. Ballard, T. E.; Wang, X.; Olekhnovich, I.; Koerner, T.; Seymour, C.; Hoffman, P. S.; Macdonald, T. L. Biological activity of modified and exchanged 2-amino-5-nitrothiazole amide analogues of nitazoxanide. Bioorg. Med. Chem. Lett., 2010, 20 (12), 3537-3539.
33. Shamir, E. R.; Warthan, M.; Brown, S. P.; Nataro, J. P.; Guerrant, R. L.; Hoffman, P. S. Nitazoxanide inhibits biofilm production and hemagglutination by enteroaggregative Escherichia coli strains by blocking assembly of AafA fimbriae. Antimicrob. Agents Chemother., 2010, 54 (4), 1526-1533.
34. de Carvalho, L. P.; Lin, G.; Jiang, X.; Nathan, C. Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. J. Med. Chem., 2009, 52 (19), 5789-5792.
35. de Carvalho, L. P.; Darby, C. M.; Rhee, K. Y.; Nathan, C., Nitazoxanide Disrupts Membrane Potential and Intrabacterial pH Homeostasis of Mycobacterium tuberculosis. ACS Med. Chem. Lett., 2011, 2 (11), 849-854.
36. Tchouaffi-Nana, F.; Ballard, T. E.; Cary, C. H.; Macdonald, T. L.; Sifri, C. D.; Hoffman, P. S. Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces. Antimicrob. Agents Chemother., 2010, 54 (7), 2767-2774.
37. Cortes, H.C. Mueller, N.; Esposito, M.; Leitão, A.; Naguleswaran, A; Hemphill, A. In vitro efficacy of nitro-and bromo-thiazolylsalicylamide compounds (thiazolides) against Besnoitia besnoiti infection in Vero cells. Parasitology, 2007, 134, 975-985.
38. Gargala, G.; Le Goff, L.; Ballet, J. J.; Favennec, L.; Stachulski, A. V.; Rossignol, J. F. Evaluation of new thiazolide/thiadiazolide derivatives reveals nitro group-independent efficacy against in vitro development of Cryptosporidium parvum. Antimicrob. Agents Chemother., 2010, 54 (3), 1315-1318.
39. Viel, H.; Rocques, H.; Martin, J.; Chartier, C. Efficacy of nitazoxanide against experimental cryptosporidiosis in goat neonates. Parasitol. Res., 2007, 102 (1), 163-166.
40. Ollivett, T. L.; Nydam, D. V.; Bowman, D. D.; Zambriski, J. A.; Bellosa, M. L.; Linden, T. C.; Divers, T. J. Effect of nitazoxanide on cryptosporidiosis in experimentally infected neonatal dairy calves. J. Dairy Sci., 2009, 92 (4), 1643-1648.
41. Schnyder, M.; Kohler, L.; Hemphill, A.; Deplazes, P. Prophylactic and therapeutic efficacy of nitazoxanide against Cryptosporidium parvum in experimentally challenged neonatal calves. Vet. Parasitol., 2009, 160 (1-2), 149-154.
42. Amadi, B.; Mwiya, M.; Sianongo, S.; Payne, L.; Watuka, A.; Katubulushi, M.; Kelly, P. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC Infect. Dis., 2009, 9, 195.
43. Debache, K.; Guionaud, C.; Kropf, C.; Boykin, D.; Stephens, C. E.; Hemphill, A. Experimental treatment of Neospora caninum-infected mice with the arylimidamide DB750 and the thiazolide nitazoxanide. Exp. Parasitol., 2011, 129 (2), 95-100.
44. Rossignol, J. F.; Abu-Zekry, M.; Hussein, A.; Santoro, M. G. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 2006, 368 (9530), 124-129.
45. Rossignol, J. F.; El-Gohary, Y. M. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment. Pharmacol. Ther. 2006, 24 (10), 1423-1430.
46. Korba, B. E.; Elazar, M.; Lui, P.; Rossignol, J. F.; Glenn, J. S. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob. Agents Chemother., 2008, 52 (11), 4069-4671.
47. Korba, B. E.; Montero, A. B.; Farrar, K.; Gaye, K.; Mukerjee, S.; Ayers, M. S.; Rossignol, J. F. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral. Res., 2008, 77 (1), 56-63.
48. Ashton, L. V.; Callan, R. L.; Rao, S.; Landolt, G. A. In Vitro Susceptibility of Canine Influenza A (H3N8) Virus to Nitazoxanide and Tizoxanide. Vet. Med. Int., 2010, Article ID 891010
49. Rossignol, J. F.; Kabil, S. M.; El-Gohary, Y.; Elfert, A.; Keeffe, E. B. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment. Pharmacol. Ther., 2008, 28 (5), 574-580.
50. Rossignol, J. F.; Elfert, A.; El-Gohary, Y.; Keeffe, E. B. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology, 2009, 136 (3), 856-862.
51. Rossignol, J. F.; Elfert, A.; Keeffe, E. B. Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide. J. Clin. Gastroenterol., 2010, 44 (7), 504-509.
52. Kabil, S. M.; Soliman, M. S.; Youssef, S. M.; Mounier, B. I. A controlled study of nitazoxanide (NTZ) 3 years after treatment of hepatitis C genotype 4. J. Egypt. Soc. Parasitol., 2011, 41 (2), 251-261.
53. Laufer, N.; Abusamra, L.; Bolcic, F.; Gun, A.; Rolón, M. J.; Pérez, H.; Krolewiecki, A.; Salomón, H.; Quarleri, J.; Cahn, P. No reduction of HCV viral load in HIV patients co-infected with HCV genotype 1 during a 30days course of nitazoxanide monotherapy. Antiviral Res., 2011, 92 (3), 497-499.
54. Siddiq, D. M.; Koo, H. L.; Adachi, J. A.; Viola, G. M. Norovirus gastroenteritis successfully treated with nitazoxanide. J. Infect., 2011, 63 (5), 394-397.
55. Teran, C. G.; Teran-Escalera, C. N.; Villarroel, P. Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children. Int. J. Infect. Dis., 2009, 13 (4), 518-523.
56. Chan-Bacab, M. J.; Hernández-Núñez, E.; Navarrete-Vázquez, G. Nitazoxanide, tizoxanide and a new analogue [4-nitro-N-(5-nitro-1,3-thiazol-2-yl)benzamide; NTB] inhibit the growth of kinetoplastid parasites (Trypanosoma cruzi and Leishmania mexicana) in vitro. J. Antimicrob. Chemother., 2009, 63 (6), 1292-1293.
57. Zhang, R.; Shang, L.; Jin, H.; Ma, C.; Wu, Y.; Liu, Q.; Xia, Z.; Wei, F.; Zhu, X. Q.; Gao, H. In vitro and in vivo antileishmanial efficacy of nitazoxanide against Leishmania donovani. Parasitol. Res., 2010, 107 (2), 475-479.
58. Müller, J.; Sidler, D.; Nachbur, U.; Wastling, J.; Brunner, T.; Hemphill, A. Thiazolides inhibit growth and induce glutathione-S-transferase pi (GSTP1)-dependent cell death in human colon cancer cells. Int. J. Cancer, 2008, 123, 1797-1806.
59. Adagu, I. S.; Nolder, D.; Warhurst, D. C.; Rossignol, J. F. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. Chemother., 2002, 49 (1), 103-111.
60. Müller, J.; Rühle, G.; Müller, N.; Rossignol, J. F.; Hemphill, A. In vitro effects of thiazolides on Giardia lamblia WB clone C6 cultured axenically and in coculture with Caco2 cells. Antimicrob. Agents Chemother., 2006, 50 (1), 162-170.
61. Pankuch, G. A.; Appelbaum, P. C. Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species. Antimicrob. Agents Chemother., 2006, 50 (3), 1112-1117.
62. Sisson, G.; Goodwin, A.; Raudonikiene, A.; Hughes, N. J.; Mukhopadhyay, A. K.; Berg, D. E.; Hoffman, P. S. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob. Agents Chemother., 2002, 46 (7), 2116-2123.
63. Hoffman, P. S.; Sisson, G.; Croxen, M. A.; Welch, K.; Harman, W. D.; Cremades, N.; Morash, M. G. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob. Agents Chemother., 2007, 51 (3), 868-876.
64. Müller, J.; Wastling, J.; Sanderson, S.; Müller, N.; Hemphill, A. A novel Giardia lamblia nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides. Antimicrob. Agents Chemother., 2007, 51 (6), 1979-1986.
65. Nillius, D.; Müller, J.; Müller, N. Nitroreductase (GlNR1) increases susceptibility of Giardia lamblia and Escherichia coli to nitro drugs. J. Antimicrob. Chemother., 2011, 66, 1029-1035.
66. Müller, J.; Naguleswaran, A.; Müller, N.; Hemphill, A. Neospora caninum: functional inhibition of protein disulfide isomerase by the broad-spectrum anti-parasitic drug nitazoxanide and other thiazolides. Exp. Parasitol., 2008, 118 (1), 80-88.
67. Müller, J.; Sterk, M.; Hemphill, A.; Müller, N. Characterization of Giardia lamblia WB C6 clones resistant to nitazoxanide and to metronidazole. J. Antimicrob. Chemother., 2007, 60 (2), 280-287.
68. Müller, J.; Hemphill, A. Identification of a host cell target for the thiazolide class of broad-spectrum anti-parasitic drugs. Exp. Parasitol., 2011, 128 (2), 145-150.
69. Hemphill, A., Müller, J. Alveolar and cystic echinococcosis: towards novel chemotherapeutical treatment options. J. Helminthol., 2009, 83, 99-111.
70. Wright, J. M.; Dunn, L. A.; Kazimierczuk, Z.; Burgess, A. G.; Krauer, K. G.; Upcroft, P.; Upcroft, J. A. Susceptibility in vitro of clinically metronidazole-resistant Trichomonas vaginalis to nitazoxanide, toyocamycin, and 2-fluoro-2'-deoxyadenosine. Parasitol. Res., 2010, 107 (4), 847-853.
71. Müller, J.; Ley, S.; Felger, I.; Hemphill, A.; Müller, N. Identification of differentially expressed genes in a Giardia lamblia WB C6 clone resistant to nitazoxanide and metronidazole. J. Antimicrob. Chemother., 2008, 62 (1), 72-82.
72. Yon, C.; Viswanathan, P.; Rossignol, J. F.; Korba, B., Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells. Antiviral Res., 2011, 91 (3), 233-240.
73. Sidler D. Brockmann, A.; Mueller, J.; Nachbur, U.; Corazza, N.; Renzulli, P.; Hemphill, A.; Brunner, T. Thiazolide-induced apoptosis in colorectal cancer cells is mediated via the Jun kinase-Bim axis and reveals glutathione-S-transferase P1 as Achilles' heel. Oncogene, 2011, in press.
74. Elazar, M.; Liu, M.; McKenna, S. A.; Liu, P.; Gehrig, E. A.; Puglisi, J. D.; Rossignol, J. F.; Glenn, J. S. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology, 2009, 137 (5), 1827-1835.